BioSpace News Archive

Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.

Zealand Pharma A/S, a biotechnology company focused on the discovery, development and commercialization of innovative peptide-based medicines, announced financial results for the 12-month period from January 1 to December 31, 2021.

March 11, 2022
·
20 min read
ENT Medical Devices Market Analysis, Development, Opportunities, Future Growth and Business Prospects by Forecast To 2028

The report further provides details about each segments and regions covered in the global ENT Medical Devices market. The data has been collected through extensive primary and secondary research and is validated by experts in the industry.

March 11, 2022
·
7 min read
Urinary Stone Treatment Device Market Trends, Revenue, Key Players, Growth, Share and Forecast Till 2028

The global pharma & healthcare market report points out the key trends and developments taking place in this business space in the ongoing COVID-19 times.

March 11, 2022
·
7 min read
iQure Pharma Meets Lipinski’s (Pfizer’s) Rule of Five with Analgesic Compound for Neuropathic Pain

Developed as a therapeutic for neuropathic pain, iQ-008 shows significant effects in all pain models.

March 11, 2022
·
1 min read
Job Trends

STUDY SHOWS PFIZER VACCINE IS MODERATELY EFFECTIVE AGAINST OMICRON FOR CHILDREN 5-15

A new study by the Centers for Disease Control and Prevention (CDC) and Abt Associates shows that the Pfizer-BioNTech COVID-19 vaccine is moderately effective against the Omicron variant for children ages 5-15.

March 11, 2022
·
2 min read
Policy

Philips Collaboration Live integrated tele-ultrasound expands FDA 510(k) clearance for remote diagnostic use to additional mobile platforms

Amsterdam, the Netherlands – Royal Philips, a global leader in health technology, announced that Collaboration Live has received expansion of its U.S. Food & Drug Administration 510 market clearance for remote diagnostic use on additional mobile platforms.

March 11, 2022
·
5 min read
Drug Development

The Result of the Phase 3 Study for Prestige BioPharma’s Herceptin Biosimilar, HD201(Tuznue®), Published in JAMA Oncology

Prestige BioPharma Limited, a Singapore-based biopharmaceutical with operations in USA and South Korea, announced positive efficacy and safety results of the Phase 3 study for HD201, a biosimilar to Herceptin®, published in JAMA Oncology on March 4, 2022.

March 11, 2022
·
2 min read
Deals

Novan Acquires EPI Health, a Specialty Dermatology Company

Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced its acquisition of EPI Health, LLC (“EPI Health”), a specialty pharmaceutical company focused on the U.S. dermatology market.

March 11, 2022
·
7 min read
Deals

Oxford Biomedica broadens its viral vector capabilities with the launch of Oxford Biomedica Solutions, a full scope AAV business in Boston, following closing of its deal with Homology

Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or the “Company”), a leading gene and cell therapy group, is pleased to announce that it has completed its deal with Homology Medicines Inc.

March 11, 2022
·
4 min read
Avadel Announces New Positive Data for Once-at-Bedtime FT218 for Narcolepsy and Once-Nightly Dosing Preference Among Patients and Clinicians at World Sleep 2022

Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data will be presented in eight posters at the World Sleep 2022 congress in Rome.

March 11, 2022
·
8 min read